Clinical and Pathological Implications of Concurrent Autoimmune Thyroid Disorders and Papillary Thyroid Cancer

Table 1

Last twenty years of published results. Autoimmune manifestation was significantly correlated with the presence of follow-up features, disease presentation features, and individual features.

Reference	Autoimmune manifestation	Type of thyroid cancer	Number of patients	Follow-up features	Disease presentation features	Individual features	Geographic widespread	Concurrent CLT in thyroid cancer (%)
[33]	Lymphocytic infiltration	PTC	95	Relapse-free	Circulating autoantibodies, coexisting thyroid disease	None	Japan	37.89
[34]	Chronic lymphocytic thyroiditis	PTC	1533	Relapse-free, overall survival	None	None	Japan	18.09
[35]	Chronic lymphocytic thyroiditis	PTC	69	None	Multifocality	None	Japan	21.74
[36]	Lymphocytic infiltration	PTC+FTC+; MTC+ATC	153	None	Low pT stage	None	Germany	17.65
[37]	Both Hashimoto's thyroiditis and lymphocytic infiltration	PTC+FTC	631	Low cancer recurrence rate, low cancer mortality rate	Low extrathyroidal invasion, nodal metastases, distant metastases, pTNM stage	Female	USA	20.28
[28]	Hashimoto's thyroiditis and lymphocytic infiltration separately	PTC	136	Overall survival	Multifocality, Tumor Infiltrating lymphocytes	Young, female	USA	30.15
[38]	Circulating autoantibodies and history of autoimmune thyroid disease	PTC+FTC	173	Relapse-free, overall survival	None	None	Brazil	8.67% (+TPOAb) + 6.94% (+TgAb) + 13.87% (with Graves or Hashimoto history)
[39]	Hashimoto's thyroiditis	PTC	101	None	None	Old	Korea	36.6
[40]	Chronic lymphocytic thyroiditis	PTC	1441	Relapse-free	Small tumors, low pTNM stage	Female	Korea	14.85
[41]	Lymphocytic infiltration and/or circulating autoantibodies	PTC	343	None	None	None	Italy	37.31
[42]	Chronic lymphocytic thyroiditis	PTMC	323	None	TgAb positive, Microsomal Ab positive, multifocality, and bilaterality	Female	Korea	32.51

PTC: papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; PTMC: papillary thyroid microcarcinoma; MTC: medullary thyroid carcinoma; ATC: anaplastic thyroid carcinoma; Ab: antibody.